A set of completely human BCMA-binding scFVs has been introduced by Bu et al. and has shown that this BCMA-specific antigen is commonly recurrent and resistant to treatment in phase I patients with multiple myeloma [65]. Here, TNFRSF17 is linked to plasma cell myeloma.